|
|
|
|
Diabetes Mellitus, Inflammation, Obesity: Proposed Treatment Pathways for Current and Future Therapies
Sonnett TE et al.Diabetes Mellitus, Inflammation, Obesity: Proposed Treatment Pathways for Current and Future Therapies.
|
|
|
Acute Hyperhomocysteinemia Impairs Endothelium Function in Subjects with Type 2 Diabetes Mellitus
Doupis J et al.FMD throughout the experiment expressed as area under the curve (AUC) was significantly lower after the M than after the W load. Consistent with impairment in endothelial function, the AUC of AI was significantly higher after the M than...
|
|
|
TopAbstracts in Cholesterol/Lipid Disorders 03/18/2010
Recent news - Cholesterol/Lipid Disorders Rosuvastatin Reduces Risk of Death in Patients With CKD, Elevated C-Reactive Protein: Presented at ACC- (DGDispatch) Vitamin D Levels Not Associated With Myalgia in Patients Taking Atorvastatin: Presented at ACC- ...
|
|
|
TopAbstracts in Vascular Disorders 03/18/2010
TopAbstracts in Vascular Disorders are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed journals are...
|
|
|
U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults
BristolMyers Squibb Company and AstraZeneca announced that the U.S.Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza And Extended Release Metformin For The Treatment Of Type 2 Diabetes ...
|
|
|
Prognostic Value of an Exaggerated Exercise Blood Pressure Response in Patients With Diabetes Mellitus and Known or Suspected Coronary Artery Disease
BouzasMosquera A et al.The results remained consistent in the subgroup of patients without a known history of CAD. Prognostic Value of an Exaggerated Exercise Blood Pressure Response in Patients With Diabetes Mellitus and Known or Suspected...
|
|
|
U.S. Food And Drug Administration Accepts New Drug Application For Once-Daily Fixed Dose Combination Of Onglyza (Saxagliptin) And Extended Release Metformin For The Treatment Of Type 2 Diabetes Mellitus In Adults
PRINCETON, N.J.& WILMINGTON, Del.-- (BUSINESS WIRE) -- (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for an investigational fixed dose...
|
|
|
Individualizing Therapies in Type 2 Diabetes Mellitus Based on Patient Characteristics: What We Know and What We Need to Know
Smith RJ et al.Recent advances in genetics, such as the identification of Kir6.2 mutations and the responsible genes for several forms of maturity onset diabetes of the young (MODY), have established precedents linking specifically effective therapies to...
|
|
|
Gestational Diabetes Mellitus
_ Gestational Diabetes Mellitus.
|
|
|
ACC: Fibrate+statin therapy do not lower CV events in adult diabetics
ATLANTATreating multiple blood lipids with combination drug therapy of a fibrate and a statin did not reduce the combined risk of cardiovascular disease events more than treatment with statin alone, according to the ACCORD trial presented today at the late...
|
|
|
ACC: Intensive BP lowering does not reduce CV events in adult diabetics
ATLANTALowering blood pressure to below currently recommended levels did not significantly reduce the combined risk of fatal or nonfatal cardiovascular disease events in adults with type 2 diabetes who were at especially high risk for cardiovascular events,...
|
|
|
Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) announced the commencement of the ' ' trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA?(saxagliptin), a...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
PRINCETON, N.J.& WILMINGTON, Del.--(HSMN NewsFeed)--Bristol-Myers Squibb Company (NYSE: BMY ) and AstraZeneca (NYSE: AZN ) today announced the commencement of the 'Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes ...
|
|
|
Bristol-Myers Squibb and AstraZeneca Initiate the Saxagliptin Assessment of Vascular Outcomes in Patients with Diabetes Mellitus
Bristol-Myers Squibb Company and AstraZeneca have announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
|
|
Bristol-Myers Squibb and AstraZeneca Initiate the Saxagliptin Ass...
Company: Bristol-Myers Squibb Co.(BMY) Bristol-Myers Squibb Company and AstraZeneca have announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a...
|
|
|
Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus
Masuda T et al.Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus.
|
|
|
Stem Cell Treatment for Diabetes Mellitus
Stem cell therapy has the potential to revolutionize the treatment of a variety of human conditions.FOR IMMEDIATE RELEASE PR Log (Press Release) Mar 11, 2010 Stem cell therapy has the potential to revolutionize the treatment of a variety of human conditions....
|
|
|
Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the Am
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
Gestational Diabetes Mellitus: NICE for the U.S.? A Comparison of the American Diabetes Association and the Am
In order to use Medscape, your browser must be set to accept cookies delivered by the Medscape site.To find out how to adjust your browser settings to accept cookies, please click here. Medscape uses cookies to customize the site based on the information...
|
|
|
BMS & AstraZeneca begin phase-4 trial of Saxgliptin in type-2 diabetes with cardio risk factors
Bristol-Myers Squibb Company and AstraZeneca announced the commencement of the "Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus" trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
|
|
Beneficial Effects of L- and N-type Calcium Channel Blocker on Glucose and Lipid Metabolism and Renal Function in Patients with Hypertension and Type II Diabetes Mellitus
It has been proved that cilnidipine has N-type calcium channels inhibitory activity as well as L-type calcium channels and inhibits excessive release of norepinephrine from the sympathetic nerve ending.This study was undertaken to compare the efficacy of...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
BristolMyers Squibb Company and AstraZeneca announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial, a multicenter, randomized, doubleblind, placebocontrolled Phase 4 Bristol...
|
|
|
Bristol-Myers Squibb and AstraZeneca announce the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial
BristolMyers Squibb Company and AstraZeneca announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial, a multicenter, randomized, doubleblind, placebocontrolled Phase 4 study, to...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
PRINCETON, N.J.& WILMINGTON, Del.(BUSINESS WIRE) Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes ...
|
|
|
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outco
- (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced the commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus trial (SAVOR-TIMI 53), a multicenter, randomized, double-blind, placebo...
|
